[{"orgOrder":0,"company":"Clinedem","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clinedem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clinedem \/ Alfasigma","highestDevelopmentStatusID":"9","companyTruncated":"Clinedem \/ Alfasigma"},{"orgOrder":0,"company":"Value Outcomes Ltd.","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Value Outcomes Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Value Outcomes Ltd. \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Value Outcomes Ltd. \/ Alfasigma"},{"orgOrder":0,"company":"Centro Medico del Noroeste","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centro Medico del Noroeste","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centro Medico del Noroeste \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Centro Medico del Noroeste \/ Alfasigma"}]

Find Clinical Drug Pipeline Developments & Deals for Sulodexide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Centro Medico del Noroeste

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Centro Medico del Noroeste

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2022

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Alfasigma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Value Outcomes Ltd.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Value Outcomes Ltd.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Vessel

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 13, 2021

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Alfasigma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Clinedem

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Clinedem

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 23, 2020

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Alfasigma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 12, 2017

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Poseidon CRO

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Bama GeVe, S.L.U.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Bama GeVe, S.L.U.

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 31, 2015

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Sun Yat-sen University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Sun Yat-sen University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 16, 2011

                          Lead Product(s) : Sulodexide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase IV

                          Sponsor : ALFA WASSERMANN(BJ) Market Research and Management Co., Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank